Binhui Bio received 300 million RMB B+ round of financing

Binhui Bio is a research and development manufacturer of anti-tumor drugs. Its main product is recombinant oncolytic type II herpes simplex virus (OH2) injection, which is suitable for lung cancer, head and neck tumors, lymphoma, liver cancer, melanoma and other diseases. It can be used in combination with traditional radiotherapy and chemotherapy to improve efficacy and reduce side effects for users. Recently, it announced that it has received nearly 300 million yuan in B+ round of financing. This round of financing was led by Yangzijiang Pharmaceutical Group, and jointly invested by Denuo Capital, Jiuzhoutong Group, Xiaoming Investment, and Hubei High Investment.

This article is reproduced from:
This site is for inclusion only, and the copyright belongs to the original author.

Leave a Comment